Bosma arhinia microphthalmia syndrome
| Bosma arhinia microphthalmia syndrome | |
|---|---|
| Synonyms | BAMS |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Arhinia, microphthalmia, hypogonadotropic hypogonadism, anosmia |
| Complications | N/A |
| Onset | Congenital |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | Clinical examination, genetic testing |
| Differential diagnosis | Kallmann syndrome, CHARGE syndrome |
| Prevention | N/A |
| Treatment | Symptomatic treatment, hormone replacement therapy |
| Medication | N/A |
| Prognosis | N/A |
| Frequency | Extremely rare |
| Deaths | N/A |
Bosma Arhinia Microphthalmia Syndrome
Bosma Arhinia Microphthalmia Syndrome (BAMS) is a rare genetic disorder characterized by the absence of the nose (arhinia) and abnormalities of the eyes, particularly microphthalmia, where one or both eyes are abnormally small. This condition is extremely rare, with only a few cases reported in the medical literature.
Clinical Features[edit]
Individuals with Bosma Arhinia Microphthalmia Syndrome typically present with the following features:
- Arhinia: Complete or partial absence of the external nose and nasal passages.
- Microphthalmia: One or both eyes are underdeveloped, leading to vision impairment.
- Midline Facial Defects: Other midline facial anomalies may be present, such as cleft lip or palate.
- Hypogonadotropic Hypogonadism: A condition affecting the production of hormones that direct sexual development, leading to delayed or absent puberty.
Genetic Basis[edit]
BAMS is caused by mutations in the SMCHD1 gene, which plays a role in chromatin remodeling and gene expression regulation. The inheritance pattern of BAMS is autosomal dominant, meaning a single copy of the mutated gene can cause the disorder.
Diagnosis[edit]
Diagnosis of Bosma Arhinia Microphthalmia Syndrome is based on clinical evaluation, identification of characteristic physical features, and genetic testing to confirm mutations in the SMCHD1 gene.
Management[edit]
Management of BAMS is symptomatic and supportive, involving a multidisciplinary team approach:
- Surgical Interventions: Reconstructive surgery may be necessary to address facial anomalies and improve nasal function.
- Ophthalmologic Care: Regular eye examinations and interventions to manage vision problems.
- Endocrinological Treatment: Hormone replacement therapy may be required for individuals with hypogonadotropic hypogonadism.
Prognosis[edit]
The prognosis for individuals with Bosma Arhinia Microphthalmia Syndrome varies depending on the severity of symptoms and associated complications. Early intervention and comprehensive care can improve quality of life.
Research and Future Directions[edit]
Research into the genetic and molecular mechanisms underlying BAMS is ongoing, with the aim of developing targeted therapies and improving diagnostic techniques. Advances in genetic testing and personalized medicine hold promise for better management of this rare condition.
See Also[edit]
References[edit]
External Links[edit]
- [Genetic and Rare Diseases Information Center (GARD)](https://rarediseases.info.nih.gov/)
- [National Organization for Rare Disorders (NORD)](https://rarediseases.org/)
NIH genetic and rare disease info[edit]
Bosma arhinia microphthalmia syndrome is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Bosma arhinia microphthalmia syndrome
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian